Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia.

Kinon BJ, Gómez JC.

Neuropharmacology. 2013 Mar;66:82-6. doi: 10.1016/j.neuropharm.2012.06.002.

PMID:
22722029
2.

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.

Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, Walling DP.

BMC Psychiatry. 2013 May 22;13:143. doi: 10.1186/1471-244X-13-143.

3.

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.

Stauffer VL, Millen BA, Andersen S, Kinon BJ, Lagrandeur L, Lindenmayer JP, Gomez JC.

Schizophr Res. 2013 Nov;150(2-3):434-41. doi: 10.1016/j.schres.2013.08.020.

PMID:
24035403
4.

Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?

Hopkins CR.

ACS Chem Neurosci. 2013 Feb 20;4(2):211-3. doi: 10.1021/cn400023y.

5.
7.

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.

Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N; HBBI Study Group..

J Clin Psychopharmacol. 2011 Jun;31(3):349-55. doi: 10.1097/JCP.0b013e318218dcd5.

PMID:
21508856
8.

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.

Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, Brenner R, Rayle TJ, Nisenbaum L, Zhao F, Gomez JC.

BMC Psychiatry. 2014 Dec 10;14:351. doi: 10.1186/s12888-014-0351-3.

9.

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.

Fell MJ, McKinzie DL, Monn JA, Svensson KA.

Neuropharmacology. 2012 Mar;62(3):1473-83. doi: 10.1016/j.neuropharm.2011.06.007. Review.

PMID:
21704048
10.

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.

Liu W, Downing AC, Munsie LM, Chen P, Reed MR, Ruble CL, Landschulz KT, Kinon BJ, Nisenbaum LK.

Pharmacogenomics J. 2012 Jun;12(3):246-54. doi: 10.1038/tpj.2010.90.

PMID:
21173788
11.

[The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].

Mosolov SN, Smulevich AB, Neznanov NG, Tochilov VA, Andreev BV, Avedisova AS, Bardenshteń≠n LM, Gurovich IIa, Reznik AM, Zharkova NB, Martenyi F.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(7):16-23. Russian.

PMID:
20639852
12.

[Targeting metabotropic glutamate receptors to develop novel antipsychotics].

Chaki S, Yoshida S, Okuyama S.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Nov;30(5-6):207-13. Review. Japanese.

PMID:
21226317
13.

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Bishara D, Taylor D.

Drugs. 2008;68(16):2269-92. doi: 10.2165/0003495-200868160-00002. Review.

PMID:
18973393
14.

Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies.

Ayan-Oshodi M, Wondmagegnehu ET, Lowe SL, Kryzhanovskaya L, Walker DJ, Kinon BJ.

J Clin Psychopharmacol. 2012 Jun;32(3):408-11. doi: 10.1097/JCP.0b013e3182542633.

PMID:
22544017
15.

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.

Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC.

Schizophr Res Treatment. 2014;2014:758212. doi: 10.1155/2014/758212.

16.

Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.

Kinon BJ, Millen BA, Zhang L, McKinzie DL.

Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016.

PMID:
25890643
17.

The search for novel antipsychotics: pharmacological and molecular targets.

Sanger DJ.

Expert Opin Ther Targets. 2004 Dec;8(6):631-41. Review.

PMID:
15584867
18.

Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.

Jones MP, Nicholl D, Trakas K.

Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99.

PMID:
20497747
19.

Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).

Annes WF, Long A, Witcher JW, Ayan-Oshodi MA, Knadler MP, Zhang W, Mitchell MI, Cornelissen K, Hall SD.

J Pharm Sci. 2015 Jan;104(1):207-14. doi: 10.1002/jps.24226.

PMID:
25382826
20.

Evolution of schizophrenia drugs: a focus on dopaminergic systems.

Nikam SS, Awasthi AK.

Curr Opin Investig Drugs. 2008 Jan;9(1):37-46. Review.

PMID:
18183530

Supplemental Content

Support Center